Why the study?
Does dipyridamole thallium-201 perfusion imaging identify myocardial perfusion defects in hemodialysis patients with and without angina?
Does dipyridamole thallium-201 perfusion imaging identify myocardial perfusion defects in hemodialysis patients with and without angina?
Dipyridamole thallium-201 imaging reveals a high prevalence of silent myocardial perfusion defects in asymptomatic hemodialysis patients, suggesting ischemic heart disease is underdiagnosed when relying on clinical symptoms alone.
Answers are grounded in this paper and cite their sources.
Perfusion imaging may detect silent ischemia in hemodialysis patients; leaves open whether it should guide management.
To assess the usefulness of dipyridamole thallium perfusion imaging in the evaluation of myocardial perfusion in hemodialysis (HD), we studied 29 HD patients divided into three groups: A) 13 patients with clinical angina, B) 8 patients without angina but similar in age, sex, time on HD and hematocrit and C) 8 young asymptomatic patients (mean age 33 +/- 9.7 years). Dipyridamole thallium-201 (Tl-201) perfusion imaging revealed myocardial perfusion defects in 8 patients (61%) from group A, 4 (50%) from group B and 1 (12.5%) from group C. These defects were localized in the inferior, posterior and septal segments of the left ventricle. Abnormal myocardial perfusion was associated with age over 50 years and aortic calcifications (p less than 0.05). Eight patients died within the following four years. All had aortic calcifications (p less than 0.001). Our results show that myocardial perfusion defects are frequent even in non-symptomatic HD patients. This suggests that ischemic heart disease could be more frequent than estimated by clinical symptoms alone. Tl-201 scintigraphy may be a useful non-invasive procedure in cardiological evaluation of HD patients.
No takes yet. Share an insight, caveat, or question.
Marcén et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: